Baxter, bioMérieux make deal on kidney test

By LabPulse.com staff writers

September 16, 2020 -- Baxter International has entered into an agreement with bioMérieux to exclusively distribute a new acute kidney injury test in Europe and the U.S.

The Nephrocleartm CCL14 test is in development for use in assessing the risk of developing persistent severe acute kidney injury (AKI). The agreement is part of a previously announced collaboration between the companies to improve identification and treatment of AKI.

Both will share in-country commercialization, while bioMérieux will retain control over the regulatory approval process

Biopsies show COVID-19 kidney injury not caused by virus in tissue
Researchers have found that COVID-19 disease leads to acute kidney injury in almost 40% of hospitalized patients, and biopsies of the organ show that...
RenalytixAI partners with University of Michigan
RenalytixAI is teaming up with the University of Michigan to extend the application of its KidneyIntelX platform to an expanded population of patients...
AI-driven DNA methylation liquid biopsy shows promise in brain and kidney cancer
A new liquid biopsy method based on DNA methylation and powered by artificial intelligence (AI) demonstrated promising performance at classifying brain...
CRISPR urine test helps assess kidney transplant patients
German researchers have developed a urine-based diagnostic test for kidney transplant patients that makes use of clustered regularly interspaced short...

Copyright © 2020 LabPulse.com

Last Updated ls 9/16/2020 3:42:34 PM